First Clinical Study Targeting ROR1, A Cancer Stem... (ID 471247) - BioProject

Format

Choose Destination

Accession: PRJNA471247 ID: 471247

First Clinical Study Targeting ROR1, A Cancer Stem Cell Antigen Involved In Rho-GTPase Activation (human)

See Genome Information for Homo sapiens

Navigate Across

Cirmtuzumab is a humanized monoclonal antibody that selectively targets ROR1, which is expressed on cancer stem cells (CSCs). More...

Accession	PRJNA471247; GEO: GSE114382
Data Type	Transcriptome or Gene expression
Scope	Multiisolate
Organism	Homo sapiens[Taxonomy ID: 9606] Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo; Homo sapiens
Publications	Choi MY et al., "Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.", Cell Stem Cell, 2018 Jun 1;22(6):951-959.e3
Submission	Registration date: 14-May-2018 Moores Cancer Center, University of California San Diego
Relevance	Medical

Project Data:

Parameter	Value
Data volume, Supplementary Mbytes	1

Parameter	Value
Data volume, Gbases	77
Data volume, Mbytes	31950

Supplemental Content

First Clinical Study Targeting ROR1, A Cancer Stem Cell Antigen Involved In Rho-...
First Clinical Study Targeting ROR1, A Cancer Stem Cell Antigen Involved In Rho-GTPase Activation
First Clinical Study Targeting ROR1, A Cancer Stem Cell Antigen Involved In Rho-GTPase Activation

BioProject
Heteractis crispa
Heteractis crispa
Heteractis crispa Raw sequence reads

BioProject
Homo sapiens
Homo sapiens
Comparison of the Transcriptional Profiles of Melanocytes from Dark and Light Skinned Individuals under Basal Conditions and Following Ultraviolet-B Irradiation

BioProject
Mus musculus
Mus musculus
MLL4 prepares the enhancer landscape for FoxP3 induction via chromatin looping

BioProject

Your browsing activity is empty.

Activity recording is turned off.